These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24582986)

  • 21. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.
    Petros AM; Huth JR; Oost T; Park CM; Ding H; Wang X; Zhang H; Nimmer P; Mendoza R; Sun C; Mack J; Walter K; Dorwin S; Gramling E; Ladror U; Rosenberg SH; Elmore SW; Fesik SW; Hajduk PJ
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6587-91. PubMed ID: 20870405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.
    Rezaei Araghi R; Bird GH; Ryan JA; Jenson JM; Godes M; Pritz JR; Grant RA; Letai A; Walensky LD; Keating AE
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E886-E895. PubMed ID: 29339518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
    Wan Y; Li Y; Yan C; Wen J; Tang Z
    Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2/Mcl-1 dual inhibitors.
    Liu T; Wan Y; Liu R; Ma L; Li M; Fang H
    Bioorg Med Chem; 2017 Mar; 25(6):1939-1948. PubMed ID: 28233676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
    Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
    FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors.
    Conlon IL; Van Eker D; Abdelmalak S; Murphy WA; Bashir H; Sun M; Chauhan J; Varney KM; Godoy-Ruiz R; Wilder PT; Fletcher S
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1949-1953. PubMed ID: 29705141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
    Timme CR; Gruidl M; Yeatman TJ
    Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
    Liu L; Liu R; Yang X; Hou X; Fang H
    Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of an efficient route toward meiogynin A-inspired dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins.
    Desrat S; Remeur C; Roussi F
    Org Biomol Chem; 2015 May; 13(19):5520-31. PubMed ID: 25877523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.
    Abulwerdi FA; Liao C; Mady AS; Gavin J; Shen C; Cierpicki T; Stuckey JA; Showalter HD; Nikolovska-Coleska Z
    J Med Chem; 2014 May; 57(10):4111-33. PubMed ID: 24749893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors.
    Wang Z; Xu W; Song T; Guo Z; Liu L; Fan Y; Wang A; Zhang Z
    Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 27911011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
    Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
    Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
    Luan S; Ge Q; Chen Y; Dai M; Yang J; Li K; Liu D; Zhao L
    Bioorg Med Chem Lett; 2017 May; 27(9):1943-1948. PubMed ID: 28343875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mcl-1 inhibitors: a patent review.
    Chen L; Fletcher S
    Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.
    Drennen B; Scheenstra JA; Yap JL; Chen L; Lanning ME; Roth BM; Wilder PT; Fletcher S
    ChemMedChem; 2016 Apr; 11(8):827-33. PubMed ID: 26844930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.